CVS Health (CVS) is having a "nice" start to 2025 as it posted "strong" Q1 results and cash flow generation, and ultimately lifted its annual outlook, Truist Securities said in a Thursday note.
The company's collaboration with Novo Nordisk (NVO) involving Wegovy weight loss drug looks to be an "attractive opportunity," analysts led by David MacDonald wrote.
Additionally, CVS intends to exit the Individual Exchange business next year in regions where it is an independent operator, as its management expects no "meaningful improvement" in the segment, the analysts said.
"Regarding utilization, trends remain elevated though are running broadly in-line with management expectations and the company called out signs of stabilization," the analysts said.
Truist Securities maintained its buy rating and $82 price target on CVS stock.
Shares of the company were down 1.7% in recent Friday trading.
Price: 68.26, Change: -1.20, Percent Change: -1.72
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。